Loading
Every dated change on the records linked to Squamous cell carcinoma of the lung, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Untreated metastatic non-squamous non-small-cell lung cancer without an EGFR or ALK alteration, with pemetrexed and platinum chemotherapy
Median overall survival not reached vs 14.
Nivolumab plus ipilimumab did not improve survival over nivolumab alone; the trial closed for futility.
Median overall survival 14.
Genotype-matched targeted arms (taselisib, palbociclib, AZD4547) closed for futility; nivolumab plus ipilimumab did not beat nivolumab (S1400I); ramucirumab plus pembrolizumab improved overall survival against standard care (S1800A).
First-line metastatic squamous NSCLC with gemcitabine and cisplatin
Median overall survival 9.
Overall survival significantly longer with necitumumab added to gemcitabine and cisplatin, by roughly six weeks at the median; hypomagnesaemia, rash and thromboembolism were the added toxicities.